Home How It Works Goals Protocols Lab Tests Peptides Blog About Log In Get Started

Comparison

Compounded vs. Brand Tirzepatide: What's the Difference in 2026?

Tirzepatide — the dual GIP/GLP-1 receptor agonist in Mounjaro and Zepbound — has a rapidly shifting regulatory landscape. Patients who accessed compounded tirzepatide during the shortage period now face a substantially narrowed legal path. This page explains what changed, what the narrow 503A carve-out still permits, and how to have an informed conversation with your prescribing clinician. Last reviewed: May 2026.

Regulatory landscape

The shortage resolution timeline and what changed legally for tirzepatide.

Tirzepatide entered the FDA's drug shortage list in December 2022 following explosive demand for Mounjaro. That listing created the legal foundation for widespread compounding under 503A and 503B of the FD&C Act. The shortage's resolution in December 2024 eliminated that foundation for most patients — and subsequent FDA action has continued to narrow the available compounding pathways.

Key Regulatory Dates — Tirzepatide

December 2022: FDA adds Mounjaro (tirzepatide) to the drug shortage list due to demand exceeding Eli Lilly's manufacturing capacity, creating the legal basis for both 503A and 503B compounding. (FDA GLP-1 Policy Page)

November 8, 2023: FDA approves Zepbound (tirzepatide) for chronic weight management. Zepbound is added to the shortage list in April 2024. (FDA Press Announcement)

December 19, 2024: FDA issues a revised declaratory order confirming the tirzepatide shortage is definitively resolved. Enforcement discretion periods announced: 503A pharmacies must cease shortage-based compounding by February 18, 2025; 503B outsourcing facilities by March 19, 2025. (FDA Policy Update, 12/19/2024; WSGR Legal Analysis)

March 5, 2025: U.S. District Court for the Northern District of Texas denies the Outsourcing Facilities Association's preliminary injunction in OFA v. FDA, Case No. 4:24-cv-00953 (N.D. Tex.), upholding the FDA's shortage resolution determination. (FDA Policy Page, 4/1/2026 Update)

April 2025: Eli Lilly files the first of multiple lawsuits against compounding pharmacies and telehealth platforms alleged to be continuing shortage-equivalent compounding after the legal window closed. (Holland & Knight Analysis, June 2025; NPR, April 23, 2025)

2026 FDA Actions: Narrowing Further

March 12, 2026: Eli Lilly issues an open letter disclosing laboratory findings of a chemical impurity — produced by a direct reaction between tirzepatide and vitamin B12 — in compounded combination products. Lilly also reports bacterial contamination and high endotoxin levels in some compounded samples, and notifies the FDA. (Lilly Open Letter, March 12, 2026; PharmExec)

April 1, 2026: FDA issues a clarifying reminder about conditions required for 503A and 503B exemptions, affirming that tirzepatide does not appear on the 503B bulks list or the drug shortage list. (FDA Policy Reminder, April 2026; Foley Legal Analysis)

April 30, 2026: FDA proposes formally excluding tirzepatide, semaglutide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk drug substances. Public comment period closes June 29, 2026. (FDA Press Announcement, April 30, 2026; Orrick LLP Analysis, May 2026)

As FDA Commissioner Marty Makary stated in the April 30 announcement: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need." The 503B bulks list proposal does not directly alter the separate 503A framework, which remains open in narrow documented circumstances. Discuss the current legal status with your prescribing clinician.

Side-by-side comparison

What each tirzepatide product category looks like as of May 2026.

The table below covers the four major tirzepatide product categories available to U.S. patients. Cash prices reflect typical self-pay ranges at time of writing and will vary by pharmacy, dose, and region. Sources: FDA Drug Shortage Page; Lilly LillyDirect pricing; GoodRx Zepbound Cost.

Feature Mounjaro® (tirzepatide, T2D) Zepbound® (tirzepatide, obesity/OSA) Compounded Tirzepatide — 503A Compounded Tirzepatide — 503B
FDA Status Approved (NDA 215866; May 13, 2022) Approved (NDA 217806; Nov 8, 2023 obesity; Dec 20, 2024 OSA) Not FDA-approved; state-board regulated under 503A Not FDA-approved; no current legal authorization to compound
Approved Indication Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus Chronic weight management (BMI ≥30 or ≥27 with comorbidity); moderate-to-severe obstructive sleep apnea in adults with obesity No FDA indication; compounded for individualized patient need only No current legal authorization; 503B bulks list exclusion proposed April 30, 2026
Legal Compounding Status (May 2026) Brand available; compounding only under 503A narrow documented exceptions Brand available; compounding only under 503A narrow documented exceptions Legal under 503A with documented, individualized medical necessity only — excipient allergy, non-commercial dose, or clinically justified combination Not currently authorized; shortage resolved Dec 2024; not on 503B bulks list; formal exclusion proposed
Typical Cash Price (monthly) ~$1,086/mo list; LillyDirect availability varies by dose $299/mo (2.5 mg), $399/mo (5 mg), $449/mo (7.5–15 mg) via LillyDirect Self Pay; list price ~$1,086 ~$150–$400+/mo where legally available under 503A; varies by pharmacy and dose Not legally available; any product offered at scale under this framework lacks authorization
Insurance Coverage More commonly covered for T2D; prior auth, A1C documentation, step therapy requirements Requires obesity/OSA documentation; prior auth mandatory; many plans still exclude weight-loss medications Generally not covered; cash pay only Not covered
Available Doses 2.5, 5, 7.5, 10, 12.5, 15 mg — prefilled once-weekly autoinjector pen; single-dose vials 2.5, 5, 7.5, 10, 12.5, 15 mg — prefilled autoinjector pen; single-dose vials; KwikPen multi-dose (2025) Multi-dose vial, variable concentration; custom dose possible if clinically justified N/A — not currently authorized
Manufacturing Oversight Full FDA GMP inspections; batch testing for potency, purity, and sterility; mandatory FAERS reporting Full FDA GMP; mandatory FAERS reporting State pharmacy board oversight; USP <797> sterile compounding required; no pre-market FDA review; adverse event reporting voluntary to FDA No authorized framework; any production lacks GMP oversight
Adverse Event Reporting Mandatory FDA pharmacovigilance (FAERS) Mandatory FAERS Voluntary to FDA; mandatory to state board; likely significantly underreported No mandatory reporting framework
B12 Combination Not combined; separate supplementation if clinically indicated Not combined; separate supplementation if clinically indicated B12 combinations produce a chemical impurity of unknown biological effect (Lilly open letter, March 12, 2026); discuss with clinician Not applicable; not authorized

Why tirzepatide is different

The dual GIP/GLP-1 mechanism — and why it matters for patients and regulators.

Tirzepatide is the first and only FDA-approved drug in the GIP/GLP-1 dual receptor agonist class. This distinction is not merely pharmacological — it shapes the clinical evidence base, the regulatory compounding analysis, and the risk-benefit considerations for any compounded version.

First-in-Class: Dual GIP + GLP-1 Activation

Tirzepatide is a synthetic 39-amino-acid modified peptide that simultaneously activates two incretin hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Semaglutide and other currently marketed GLP-1 drugs activate only the GLP-1 receptor. (PMC — Role of Tirzepatide, PMC7843845)

Both GIP and GLP-1 receptors are expressed in brain regions governing appetite, and both contribute to the post-meal incretin response that stimulates insulin secretion in a glucose-dependent fashion. The combined receptor activation may produce additive effects on appetite suppression, insulin secretion, glucagon suppression during hyperglycemia, and gastric emptying delay.

Head-to-Head Evidence: SURMOUNT-5

In the SURMOUNT-5 randomized controlled trial (n=751, 72 weeks) — the first head-to-head comparison of tirzepatide versus semaglutide 2.4 mg for obesity — tirzepatide produced an average weight reduction of 20.2% vs. 13.7% with semaglutide, a 47% greater relative weight loss (P<0.001). In absolute terms, participants lost 22.8 kg vs. 15.0 kg. (SURMOUNT-5, NEJM, PMID: 40353578)

Evidence suggests this superior weight reduction reflects the additive contribution of GIP receptor activation. The FDA considers tirzepatide a first-in-class medication. (Wikipedia — Tirzepatide)

Mounjaro vs. Zepbound: Same Molecule, Different Labels

Mounjaro (NDA 215866, approved May 13, 2022) and Zepbound (NDA 217806, approved November 8, 2023) contain identical tirzepatide at identical doses. Zepbound gained an additional approval for moderate-to-severe obstructive sleep apnea in adults with obesity on December 20, 2024 — the first medication ever approved for this indication.

Both products carry an FDA Boxed Warning for potential thyroid C-cell tumors (medullary thyroid carcinoma) based on animal data and are contraindicated in patients with a personal or family history of MTC or MEN 2. Discuss your complete personal and family history with your prescribing clinician.

503A carve-outs

The narrow 503A scenarios that survive shortage resolution — and those that do not.

The end of shortage-based compounding does not extinguish all 503A compounding of tirzepatide. Section 503A of the FD&C Act has always recognized that some patients have genuine, individualized medical needs a commercially available product cannot meet. The standard comes from the FDA's January 2018 guidance: a compounded product is not an essentially equivalent copy when there is "a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner." (FDA 503A Essentially a Copy Guidance, January 2018)

May Qualify: Documented Excipient Allergy

Mounjaro and Zepbound contain sodium phosphate dibasic heptahydrate, sodium chloride, and hydrochloric acid as inactive excipients — a different profile from semaglutide-based products. (DrugPatentWatch — Tirzepatide Excipients) A patient with a clinically confirmed, chart-documented allergy or intolerance to one of these specific excipients — verified by allergy testing or prior adverse reaction — may have a legitimate 503A basis for a compounded formulation excluding that ingredient.

This requires written prescriber determination that the commercially available product cannot be used, documentation of the specific allergy in the patient's chart, and a formulation meaningfully different in excipient profile from the brand.

May Qualify: Non-Commercially Available Dose

Mounjaro and Zepbound are available in a fixed 2.5–15 mg dose range with a manufacturer-established titration: begin at 2.5 mg once weekly for 4 weeks, then increase by 2.5 mg every 4 weeks. Some patients may require a prescriber-documented clinical rationale for a dose or concentration outside this range — for example, a sub-2.5 mg starting dose for documented extreme GI sensitivity, or a customized micro-titration schedule for a patient with a history of severe, hospitalization-requiring side effects at standard initiation. (Foley Legal Analysis, April 14, 2026)

Does NOT Qualify: Cost, Preference, or General Wellness

The FDA has explicitly stated that cost is not a qualifying clinical need under Section 503A. Patient preference for a vial over a pen is a convenience preference, not a clinical necessity. Adding B12 or other vitamins to a standard-dose tirzepatide formulation for general wellness does not create a clinically significant difference — and Lilly's March 2026 data indicate such combinations may introduce a chemical impurity of unknown safety. (Foley Legal Analysis; BioSpace — Lilly Litigation)

Regular, inordinate prescribing of compounded tirzepatide to all patients without individualized documentation has been the explicit focus of Lilly and FDA enforcement action. Discuss with your clinician whether any documented clinical need genuinely applies to your situation.

The 503B bulks list proposal (April 30, 2026) does not directly alter the 503A framework, which operates under a separate statutory provision for patient-specific prescriptions. However, the overall regulatory trend is toward narrowing available compounding pathways. (Orrick LLP, May 2026)

Safety considerations

FAERS data, the March 2026 B12 impurity finding, and what to look for.

Mounjaro and Zepbound are subject to full FDA GMP oversight: pre-market review, batch testing, mandatory FAERS pharmacovigilance, and cold-chain distribution. Compounded tirzepatide from a 503A pharmacy is regulated by state pharmacy boards under USP <797> standards only. This regulatory gap produces material quality risk differences that evidence suggests are not trivial.

FAERS Pharmacovigilance Data

As of July 31, 2025, the FDA had received 545 reports of adverse events associated with compounded tirzepatide. Federal law does not require 503A pharmacies to report adverse events to the FDA, making this figure likely a significant undercount. (FDA Concerns with Unapproved GLP-1 Drugs, updated April 2026)

A 2025 pharmacovigilance study published in Expert Opinion on Drug Safety (McCall et al.; PMID: 40285721; DOI: 10.1080/14740338.2025.2499670) analyzed 81,078 GLP-1 FAERS reports from 2018–2024. Of 707 involving compounded products, reporting odds ratios (ROR) for compounded vs. non-compounded products were significantly elevated:

  • Preparation errors: ROR 48.92 (95% CI 12.63–189.6)
  • Contamination events: ROR 19.00 (95% CI 4.24–85.03)
  • Manufacturing/compounding issues: ROR 8.51 (95% CI 5.17–14.0)
  • Suicidality: ROR 6.34 (95% CI 4.32–8.99)
  • Hospitalization (any AE): ROR 2.35 (95% CI 1.94–2.83)

A separate tirzepatide-specific FAERS analysis (2022–Q1 2025; n=65,974 reports) found that incorrect dose administration was the single most commonly reported adverse event, increasing 8-fold from 1,248 reports in 2022 to 9,800 in 2024, with a risk signal ROR of 22.15. (Almansour et al., Healthcare, September 2025; DOI: 10.3390/healthcare13182259)

The March 2026 Tirzepatide-B12 Impurity Finding

On March 12, 2026, Eli Lilly issued a public open letter disclosing laboratory testing results from compounded tirzepatide products combined with vitamin B12 (marketed as methylcobalamin, hydroxocobalamin, or cyanocobalamin). Lilly's testing found significant levels of a chemical impurity produced by a direct chemical reaction between tirzepatide and B12. (Lilly Open Letter, March 12, 2026; PharmExec Report, March 12, 2026)

The company disclosed that nothing is known about the impurity's short- or long-term effects in humans, its interaction with GLP-1 and GIP receptors, its toxicity, immune reactogenicity, or pharmacokinetics. Lilly's testing also found bacterial contamination and high endotoxin levels in some compounded samples — neither is present in FDA-approved Mounjaro or Zepbound. Lilly notified the FDA and requested a recall of all compounded tirzepatide products combined with B12. This finding is specific to the tirzepatide-B12 combination and represents a safety signal distinct from the semaglutide context.

Patients receiving any compounded tirzepatide containing B12 should discuss this finding with their prescribing clinician.

Dosing Error Risk

Unlike Mounjaro and Zepbound's prefilled autoinjector pens — which deliver a pre-measured dose — compounded tirzepatide is typically dispensed in multi-dose vials requiring the patient to draw up doses with a syringe. The FDA has received multiple reports of adverse events, some requiring hospitalization, related to dosing errors: patients administering 5–20 times the intended dose by misreading syringe units; healthcare providers miscalculating dose conversions between mg, mL, and "units." (Brown Health — Compounded Weight Loss Medications)

Fraudulent Products and Red Flags

The FDA has confirmed awareness of fraudulent compounded tirzepatide products bearing false pharmacy information on their labels. During 2025, the FDA issued more than 50 warning letters to compounders and telehealth distributors for misleading claims related to compounded GLP-1 products. (OnHealthcare.tech, May 2026)

Red flags: no prescription required; foreign pharmacy; "research chemical" labeling; pricing below $100/month; refusal to provide a Certificate of Analysis; products that cannot be verified as dispensed by the named pharmacy; marketing claiming equivalence to Mounjaro or Zepbound. Verify any pharmacy's licensure through your state Board of Pharmacy and the NABP at nabp.pharmacy.

Clinical evidence

SURPASS, SURMOUNT, and what the trial data does — and does not — tell us about compounded formulations.

The evidence base for tirzepatide's clinical efficacy is among the most robust in the GLP-1 class. Critically, every piece of that evidence applies to FDA-approved Mounjaro and Zepbound specifically — not to compounded formulations. Evidence suggests branded tirzepatide produces clinically meaningful weight loss and glycemic improvement; whether those outcomes translate to compounded preparations is unknown.

SURPASS Program — Type 2 Diabetes

The SURPASS Phase 3 global development program enrolled 7,769 participants across five global and two regional trials at 673 sites in 24 countries, beginning in late 2018. Key results:

SURPASS-2 vs. semaglutide 1 mg (n=1,879; 40 weeks): Tirzepatide at all doses was noninferior and superior to semaglutide for HbA1c reduction (−2.01% to −2.30% vs. −1.86%; P<0.001) and weight reduction (−7.6 to −11.2 kg vs. −5.7 kg; P<0.001 for all). (Frias et al., NEJM 2021; DOI: 10.1056/NEJMoa2107519)

SURPASS-CVOT (2025; >13,000 participants; >4.5 years): Mounjaro demonstrated non-inferior rates of major adverse cardiovascular events (MACE-3) vs. dulaglutide, with a 16% lower rate of all-cause death. (Lilly SURPASS-CVOT Announcement, July 31, 2025)

SURMOUNT Program — Obesity and Weight Management

The SURMOUNT Phase 3 program enrolled more than 5,000 adults with obesity or overweight across six trials, beginning in late 2019.

SURMOUNT-1 vs. placebo (n=2,539; 72 weeks): Average weight reductions of 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg) vs. 2.4% with placebo. Up to 63% of participants at 15 mg achieved ≥20% body weight reduction. (Lilly SURMOUNT-1 Announcement, June 4, 2022)

SURMOUNT-5 vs. semaglutide 2.4 mg (n=751; 72 weeks): Tirzepatide produced 20.2% average weight reduction vs. 13.7% with semaglutide — a 47% greater relative weight loss (P<0.001). Absolute loss: 22.8 kg vs. 15.0 kg. (SURMOUNT-5, NEJM, PMID: 40353578)

Compounded Tirzepatide: No RCT Data

No published randomized controlled trial has evaluated the safety or efficacy of compounded tirzepatide. The SURPASS and SURMOUNT data are specific to FDA-approved Mounjaro and Zepbound, manufactured under full GMP controls, using FDA-reviewed excipients, with rigorously controlled dose concentrations and sterile fill-finish processes.

Assuming clinical equivalence requires assuming the active ingredient is chemically identical and at labeled concentration, no clinically relevant impurities are present, the excipient system does not alter bioavailability, and any added ingredients do not chemically react with tirzepatide. Lilly's March 2026 finding demonstrated that the tirzepatide-B12 combination violates the final assumption — producing a compounded combination that is not pharmacologically equivalent to branded tirzepatide.

Questions for your clinician

8 questions to ask before pursuing compounded tirzepatide.

If you are considering compounded tirzepatide or are currently using it, these tirzepatide-specific questions help you and your prescribing clinician evaluate whether compounding is appropriate and legally defensible for your individual situation. Discuss with your clinician before making any change to your treatment plan.

1. Do I have a documented excipient allergy to tirzepatide's inactive ingredients?

Mounjaro and Zepbound contain sodium phosphate dibasic heptahydrate, sodium chloride, and hydrochloric acid — not phenol or propylene glycol (which are in semaglutide products). Ask your clinician to review your chart for any documented allergy or adverse reaction to these specific excipients and whether it is clinically verified with sufficient specificity to support a 503A prescription.

2. Does my situation genuinely require a dose not commercially available?

The branded tirzepatide starting dose is 2.5 mg once weekly. If you have documented extreme GI sensitivity, a history of severe nausea requiring medical intervention, or a prior inability to tolerate standard GLP-1 titration, discuss whether a clinically justified sub-2.5 mg starting dose or customized titration schedule constitutes genuine medical necessity — not merely a preference for a slower ramp.

3. Can you document the clinical rationale — specific to tirzepatide — in my chart?

For a compounded tirzepatide prescription to be legally defensible under 503A, the prescriber's determination of a "significant difference" for an identified individual patient must be documented before any prescription is issued. The rationale must be tirzepatide-specific, not a general compounding preference. Ask to review what will be in your chart.

4. Am I eligible for LillyDirect self-pay pricing?

As of December 2025, Eli Lilly lowered LillyDirect self-pay prices for Zepbound vials to $299/month (2.5 mg starting dose) and $449/month (maintenance doses). (Lilly LillyDirect announcement, December 1, 2025) These are self-injectable vials with a similar administration method to compounded products. Discuss with your clinician whether this option is accessible before assuming compounded is the only affordable path.

5. Which specific 503A pharmacy would dispense the formulation, and can I verify it?

Ask your clinician to name the specific pharmacy and confirm it is verifiable through your state's Board of Pharmacy database, NABP at nabp.pharmacy, and whether it has had any board actions or FDA inspection findings. The FDA has confirmed awareness of fraudulent products bearing licensed pharmacy names that did not compound them — verify independently.

6. Does the compounded formulation contain vitamin B12 or any combination additive?

Given Eli Lilly's March 12, 2026 finding of a chemical impurity produced by the direct reaction of tirzepatide and B12, any compounded formulation containing any form of B12 (methylcobalamin, hydroxocobalamin, or cyanocobalamin) raises a specific safety question distinct from plain tirzepatide compounding. Ask whether the pharmacy has independently tested for this impurity in their specific formulation and what those results show. (Lilly Open Letter, March 12, 2026)

7. Can the pharmacy provide a batch Certificate of Analysis?

A legitimate USP <797>-compliant 503A pharmacy can provide batch-specific documentation confirming tirzepatide identity, potency assay, sterility testing results, and endotoxin levels. Resistance or inability to provide this documentation is a significant warning sign. Ask for it before filling any compounded injectable tirzepatide prescription.

8. What is the monitoring plan and contingency if regulations change?

The FDA's April 30, 2026 proposal to formally exclude tirzepatide from the 503B bulks list (public comment closes June 29, 2026) signals continued regulatory pressure. Discuss with your clinician: what is the plan if 503A pathways narrow further? What is the adverse event reporting process? What is the transition path to brand-name LillyDirect pricing if compounding becomes unavailable? A prescriber current on the regulatory landscape should be able to answer all three. (FDA 503B Proposal, April 30, 2026)

FAQ

Common questions about compounded versus brand tirzepatide in 2026.

Is compounded tirzepatide legal in 2026?

It depends on the circumstances. The broad shortage-based authorization ended in February 2025 (503A) and March 2025 (503B). What remains is a narrow 503A pathway for individualized patients where the prescriber has documented a meaningful clinical difference — excipient allergy, non-commercially available dose, or a carefully justified combination product. Cost savings and patient preference alone do not qualify. 503B compounding is not currently authorized. (FDA Policy Page)

Is compounded tirzepatide safe?

Compounded tirzepatide carries risks that FDA-approved products do not, including elevated dosing error risk from multi-dose vials, variable sterility controls, and — for B12 combination products specifically — a chemical impurity of unknown biological effect identified by Eli Lilly in March 2026. This does not mean every compounded product is unsafe; it means the quality floor is lower and patient safety depends heavily on pharmacy selection and prescriber oversight. (Lilly Open Letter, March 12, 2026)

Why is compounded tirzepatide cheaper?

A 503A pharmacy bypasses multi-phase clinical development, FDA pre-market review, patent premiums, GMP manufacturing, and post-market surveillance — all of which are embedded in Lilly's brand pricing. Lilly lowered LillyDirect Zepbound vial pricing to $299/month (starting dose) in December 2025, narrowing but not closing the gap. The cost differential is real, but comes paired with the quality-control and regulatory differences discussed throughout this page. (Lilly LillyDirect, December 1, 2025)

What makes tirzepatide different from semaglutide?

Tirzepatide activates both GIP and GLP-1 receptors; semaglutide activates only GLP-1. In the first head-to-head RCT (SURMOUNT-5, NEJM, 2025), tirzepatide produced 47% greater relative weight loss than semaglutide 2.4 mg (20.2% vs. 13.7%; P<0.001). Tirzepatide also holds an additional FDA approval for obstructive sleep apnea — the first medication ever approved for that indication. (SURMOUNT-5, NEJM, PMID: 40353578)

What is the difference between Mounjaro and Zepbound?

Both contain identical tirzepatide at identical doses. Mounjaro is indicated for type 2 diabetes; Zepbound is indicated for chronic weight management and obstructive sleep apnea. They should not be used simultaneously. If you have both T2D and obesity, discuss with your prescribing clinician which product and indication is appropriate for your clinical situation. (Lilly Mounjaro HCP page)

Will my insurance cover compounded tirzepatide?

Generally, no. Insurance plans do not typically cover compounded medications without FDA approval. Mounjaro coverage for T2D is more common but still requires prior authorization and A1C documentation. Zepbound coverage for obesity/OSA requires qualifying documentation with mandatory prior authorization. Discuss with your clinician whether the Zepbound Savings Card ($25/month for eligible commercially insured patients) or LillyDirect self-pay vials apply to your situation before assuming compounded is the only option.

Are there sterility concerns with compounded tirzepatide?

Yes. All injectable compounded medications must meet USP <797> standards, but implementation quality varies substantially across 503A pharmacies. Lilly's March 2026 testing found bacterial contamination and high endotoxin levels in some compounded samples. Before using any compounded injectable, request the batch Certificate of Analysis demonstrating sterility testing, potency, and endotoxin results. A legitimate pharmacy can provide this documentation. (Lilly Open Letter, March 12, 2026)

What are red flags that a compounding pharmacy is not legitimate?

No valid prescription required; foreign pharmacy or products shipped from abroad; "research chemical" labeling; pricing far below market (e.g., $50–$100/month); refusal to provide a Certificate of Analysis; products that cannot be verified as dispensed by the named pharmacy; marketing claiming equivalence to Mounjaro or Zepbound. Verify pharmacy licensure through your state's Board of Pharmacy and NABP at nabp.pharmacy. Confirm FDA registration for any facility claiming 503B status. (FDA Concerns Page, updated April 2026)

Informational only. Content on this page is for educational purposes and does not constitute medical advice or legal counsel. Regulatory status described reflects FDA guidance and public notices through May 2026 and may change following pending rule-making. All prescriptions are issued at the sole discretion of the prescribing clinician. Consult a qualified healthcare attorney and pharmacy compliance specialist for legal guidance. Results vary. Last reviewed: May 2026.

Related

Continue exploring.

GLP-1 Receptor Agonists — Full Evidence Page

Mechanism of action, SURPASS and SURMOUNT trial data, safety profile, contraindications, and the full 2026 regulatory picture for tirzepatide and semaglutide — including updated compounding guidance.

Read the GLP-1 Page

Compounded vs. Brand Semaglutide

The same regulatory comparison for Ozempic and Wegovy — how the semaglutide shortage resolution timeline and 503A framework differ from tirzepatide, and what the current legal landscape looks like.

Semaglutide Comparison

Start Your Clinical Evaluation

YourHealthRx is available across all 50 states and DC. A licensed clinician reviews your health history and determines whether a tirzepatide protocol — brand or, where clinically defensible, compounded under 503A — aligns with your individual profile.

Start Your Intake

The right choice depends on your specific situation.

Mounjaro, Zepbound, or a narrow 503A compounded formulation — a clinician evaluates your individual history and clinical basis.

Start your intake and connect with a licensed prescribing clinician who is current on the 2026 tirzepatide compounding regulatory landscape, including the March 2026 B12 impurity finding and the April 30, 2026 503B bulks list proposal.

Start Your Intake GLP-1 Evidence Page